An update on the physiological and therapeutic relevance of GPCR oligomers

Pharmacological Research

Volumn 117, Issue , 2017, Pages 303-327

  Farran, Batoul ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug targets; GPCRs; Molecular therapeutics; Pathophysiological processes; Receptor heteromers; Signalling pathways

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR 1; 4 AMINOBUTYRIC ACID B RECEPTOR 2; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 179; G PROTEIN COUPLED RECEPTOR 83; GHRELIN RECEPTOR; GHRELIN RECEPTOR 1A; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; KAPPA OPIATE RECEPTOR; MELANOCORTIN 4 RECEPTOR; METABOTROPIC RECEPTOR 5; MU OPIATE RECEPTOR; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; LIGAND;

ALLOSTERISM; CELL COMPARTMENTALIZATION; CELL MIGRATION; CONFORMATIONAL TRANSITION; DIMERIZATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYDROPHOBICITY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPID RAFT; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NONHUMAN; OBESITY; OLIGOMERIZATION; PARKINSON DISEASE; PHENOTYPIC PLASTICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; ANIMAL; METABOLISM; PROTEIN SUBUNIT;

ANIMALS; DIMERIZATION; HUMANS; LIGANDS; PROTEIN SUBUNITS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85009351664     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.01.008     Document Type: Review

References (265)

1. [1] Smith, N.J., Milligan, G., Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 62:4 (2010), 701–725, 10.1124/pr.110.002667.
2. [2] Foord, S.M., Jupe, S., Holbrook, J., Bioinformatics and type II G-protein-coupled receptors. Biochem. Soc. Trans. 30:4 (2002), 473–479 (10.1042/).
3. [3] Lefkowitz, R.J., Seven transmembrane receptors: a brief personal retrospective. Biochim. Biophys. Acta 1768:4 (2007), 748–755, 10.1016/j.bbamem.2006.11.001.
4. [4] Lin, H.H., G-protein-coupled receptors and their (Bio) chemical significance win 2012 Nobel Prize in Chemistry. Biomed. J. 36:3 (2013), 118–124, 10.4103/2319-4170.113233.
5. [5] Latek, D., Modzelewska, A., Trzaskowski, B., Palczewski, K., Filipek, S., G protein-coupled receptors-recent advances. Acta Biochim. Polonica 59:4 (2012), 515–529.
6. [6] Wise, A., Gearing, K., Rees, S., Target validation of G-protein coupled receptors. Drug Disc. Today 7:4 (2002), 235–246.
7. [7] Katritch, V., Cherezov, V., Stevens, R.C., Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33:1 (2012), 17–27, 10.1016/j.tips.2011.09.003.
8. [8] Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., Yamamoto, M., Miyano, M., Crystal structure of rhodopsin: a G protein-coupled receptor. Sci (New York NY) 289:5480 (2000), 739–745.
9. [9] Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., Stevens, R.C., High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Sci. (New York, NY) 318:5854 (2007), 1258–1265, 10.1126/science.1150577.
10. [10] Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C., Burghammer, M., Ratnala, V.R., Sanishvili, R., Fischetti, R.F., Schertler, G.F., Weis, W.I., Kobilka, B.K., Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450:7168 (2007), 383–387, 10.1038/nature06325.
11. [11] Chien, E.Y., Liu, W., Zhao, Q., Katritch, V., Han, G.W., Hanson, M.A., Shi, L., Newman, A.H., Javitch, J.A., Cherezov, V., Stevens, R.C., Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Sci. (New York, NY) 330:6007 (2010), 1091–1095, 10.1126/science.1197410.
12. [12] Haga, K., Kruse, A.C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W.I., Okada, T., Kobilka, B.K., Haga, T., Kobayashi, T., Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:7386 (2012), 547–551, 10.1038/nature10753.
13. [13] Kruse, A.C., Hu, J., Pan, A.C., Arlow, D.H., Rosenbaum, D.M., Rosemond, E., Green, H.F., Liu, T., Chae, P.S., Dror, R.O., Shaw, D.E., Weis, W.I., Wess, J., Kobilka, B.K., Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:7386 (2012), 552–556, 10.1038/nature10867.
14. [14] Chun, L., Zhang, W.H., Liu, J.F., Structure and ligand recognition of class C GPCRs. Acta Pharmacol. Sin. 33:3 (2012), 312–323, 10.1038/aps.2011.186.
15. [15] Manglik, A., Kruse, A.C., Kobilka, T.S., Thian, F.S., Mathiesen, J.M., Sunahara, R.K., Pardo, L., Weis, W.I., Kobilka, B.K., Granier, S., Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485:7398 (2012), 321–326, 10.1038/nature10954.
16. [16] Granier, S., Manglik, A., Kruse, A.C., Kobilka, T.S., Thian, F.S., Weis, W.I., Kobilka, B.K., Structure of the delta-opioid receptor bound to naltrindole. Nature 485:7398 (2012), 400–404, 10.1038/nature11111.
17. [17] Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G.W., Vardy, E., Liu, W., Thompson, A.A., Huang, X.P., Carroll, F.I., Mascarella, S.W., Westkaemper, R.B., Mosier, P.D., Roth, B.L., Cherezov, V., Stevens, R.C., Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485:7398 (2012), 327–332, 10.1038/nature10939.
18. [18] Thompson, A.A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., Huang, X.P., Trapella, C., Guerrini, R., Calo, G., Roth, B.L., Cherezov, V., Stevens, R.C., Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485:7398 (2012), 395–399, 10.1038/nature11085.
19. [19] Jaakola, V.P., Griffith, M.T., Hanson, M.A., Cherezov, V., Chien, E.Y., Lane, J.R., Ijzerman, A.P., Stevens, R.C., The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Sci. (New York, NY) 322:5905 (2008), 1211–1217, 10.1126/science.1164772.
20. [20] Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G.W., Kobayashi, T., Stevens, R.C., Iwata, S., Structure of the human histamine H1 receptor complex with doxepin. Nature 475:7354 (2011), 65–70, 10.1038/nature10236.
21. [21] Palczewski, K., Oligomeric forms of G protein-coupled receptors (GPCRs). Trends Biochem. Sci. 35:11 (2010), 595–600, 10.1016/j.tibs.2010.05.002.
22. [22] Agnati, L.F., Fuxe, K., Zini, I., Lenzi, P., Hokfelt, T., Aspects on receptor regulation and isoreceptor identification. Med. Biol. 58:4 (1980), 182–187.
23. [23] Dupre, D.J., Hammad, M.M., Holland, P., Wertman, J., Role of chaperones in G protein coupled receptor signaling complex assembly. Subcell. Biochem. 63 (2012), 23–42, 10.1007/978-94-007-4765-4_2.
24. [24] Ciruela, F., Gomez-Soler, M., Guidolin, D., Borroto-Escuela, D.O., Agnati, L.F., Fuxe, K., Fernandez-Duenas, V., Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim. Biophys. Acta 1808:5 (2011), 1245–1255, 10.1016/j.bbamem.2011.02.007.
25. [25] Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D.A., Engel, A., Palczewski, K., Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421:6919 (2003), 127–128, 10.1038/421127a.
26. [26] Pin, J.P., Neubig, R., Bouvier, M., Devi, L., Filizola, M., Javitch, J.A., Lohse, M.J., Milligan, G., Palczewski, K., Parmentier, M., Spedding, M., International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 59:1 (2007), 5–13, 10.1124/pr.59.1.5.
27. [27] Rasmussen, S.G., Choi, H.J., Fung, J.J., Pardon, E., Casarosa, P., Chae, P.S., Devree, B.T., Rosenbaum, D.M., Thian, F.S., Kobilka, T.S., Schnapp, A., Konetzki, I., Sunahara, R.K., Gellman, S.H., Pautsch, A., Steyaert, J., Weis, W.I., Kobilka, B.K., Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469:7329 (2011), 175–180, 10.1038/nature09648.
28. [28] Dupré, D.J., Hébert, T.E., Jockers, R., GPCR Signaling Complexes-Synthesis, Assembly, Trafficking and Specificity, vol 63. Subcellular Biochemistry. 2012, Springer Netherlands, Dordrecht Netherlands, 10.1007/978-94-007-4765-4.
29. [29] Sciences TRSAo Scientific Background on the Nobel Prize in Chemistry 2012. Studies of G-protein coupled receptors.
30. [30] Kenakin, T., Miller, L.J., Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62:2 (2010), 265–304.
31. [31] Edelstein, S.J., Changeux, J.P., Biased allostery. Biophys. J. 111:5 (2016), 902–908.
32. [32] Fuxe, K., Marcellino, D., Borroto-Escuela, D.O., Frankowska, M., Ferraro, L., Guidolin, D., Ciruela, F., Agnati, L.F., The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J. Recept. Signal Transduct. Res. 30:5 (2010), 272–283, 10.3109/10799893.2010.506191.
33. [33] Gahbauer, S., Bockmann, R.A., Membrane-mediated oligomerization of G protein coupled receptors and its implications for GPCR function. Front. Physiol., 7, 2016, 494.
34. [34] Wright, P.T., Schobesberger, S., Gorelik, J., Studying GPCR/cAMP pharmacology from the perspective of cellular structure. Front. Pharmacol., 6(148), 2015.
35. [35] Schwencke, C., Okumura, S., Yamamoto, M., Geng, Y.J., Ishikawa, Y., Colocalization of beta-adrenergic receptors and caveolin within the plasma membrane. J. Cell Biochem. 75:1 (1999), 64–72.
36. [36] Bhatnagar, A., Sheffler, D.J., Kroeze, W.K., Compton-Toth, B., Roth, B.L., Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J. Biol. Chem. 279:33 (2004), 34614–34623, 10.1074/jbc.M404673200.
37. [37] Huang, P., Xu, W., Yoon, S.I., Chen, C., Chong, P.L., Unterwald, E.M., Liu-Chen, L.Y., Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells. Brain Res. 1184 (2007), 46–56.
38. [38] Margeta-Mitrovic, M., Jan, Y.N., Jan, L.Y., A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 27:1 (2000), 97–106.
39. [39] Ng, G.Y., Clark, J., Coulombe, N., Ethier, N., Hebert, T.E., Sullivan, R., Kargman, S., Chateauneuf, A., Tsukamoto, N., McDonald, T., Whiting, P., Mezey, E., Johnson, M.P., Liu, Q., Kolakowski, L.F. Jr., Evans, J.F., Bonner, T.I., O'Neill, G.P., Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J. Biol. Chem. 274:12 (1999), 7607–7610.
40. [40] Robbins, M.J., Calver, A.R., Filippov, A.K., Hirst, W.D., Russell, R.B., Wood, M.D., Nasir, S., Couve, A., Brown, D.A., Moss, S.J., Pangalos, M.N., GABA(B2) is essential for g-protein coupling of the GABA(B) receptor heterodimer. J. Neurosci. Off. J. Soc. Neurosci. 21:20 (2001), 8043–8052.
41. [41] Sullivan, R., Chateauneuf, A., Coulombe, N., Kolakowski, L.F. Jr., Johnson, M.P., Hebert, T.E., Ethier, N., Belley, M., Metters, K., Abramovitz, M., O'Neill, G.P., Ng, G.Y., Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GABA(B) heterodimer as the functional receptor. J. Pharmacol. Exp. Ther. 293:2 (2000), 460–467.
42. [42] Pin, J.P., Galvez, T., Prezeau, L., Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol.Ther. 98:3 (2003), 325–354.
43. [43] Franco, R., Martinez-Pinilla, E., Lanciego, J.L., Navarro, G., Basic pharmacological and structural evidence for class a G-protein-coupled receptor heteromerization. Front. Pharmacol., 7(76), 2016, 10.3389/fphar.2016.00076.
44. [44] Prezeau, L., Rives, M.L., Comps-Agrar, L., Maurel, D., Kniazeff, J., Pin, J.P., Functional crosstalk between GPCRs: with or without oligomerization. Curr. Opin. Pharmacol. 10:1 (2010), 6–13, 10.1016/j.coph.2009.10.009.
45. [45] Nelson, G., Hoon, M.A., Chandrashekar, J., Zhang, Y., Ryba, N.J., Zuker, C.S., Mammalian sweet taste receptors. Cell 106:3 (2001), 381–390.
46. [46] Gomes, I., Jordan, B.A., Gupta, A., Trapaidze, N., Nagy, V., Devi, L.A., Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J. Neurosci. Off. J. Soc. Neurosci., 20(22), 2000, RC110.
47. [47] Gines, S., Hillion, J., Torvinen, M., Le Crom, S., Casado, V., Canela, E.I., Rondin, S., Lew, J.Y., Watson, S., Zoli, M., Agnati, L.F., Verniera, P., Lluis, C., Ferre, S., Fuxe, K., Franco, R., Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. U. S. A. 97:15 (2000), 8606–8611, 10.1073/pnas.150241097.
48. [48] Scarselli, M., Novi, F., Schallmach, E., Lin, R., Baragli, A., Colzi, A., Griffon, N., Corsini, G.U., Sokoloff, P., Levenson, R., Vogel, Z., Maggio, R., D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276:32 (2001), 30308–30314, 10.1074/jbc.m102297200.
49. [49] Beaulieu, J.M., Espinoza, S., Gainetdinov, R.R., Dopamine receptors – IUPHAR review 13. Br. J. Pharmacol. 172:1 (2015), 1–23.
50. [50] Aizman, O., Brismar, H., Uhlen, P., Zettergren, E., Levey, A.I., Forssberg, H., Greengard, P., Aperia, A., Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3:3 (2000), 226–230, 10.1038/72929.
51. [51] George, S.R., O'Dowd, B.F., A novel dopamine receptor signaling unit in brain: heterooligomers of D1 and D2 dopamine receptors. Sci. World J. 7 (2007), 58–63, 10.1100/tsw.2007.223.
52. [52] Rashid, A.J., So, C.H., Kong, M.M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B.F., George, S.R., D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U. S. A. 104:2 (2007), 654–659, 10.1073/pnas.0604049104.
53. [53] So, C.H., Varghese, G., Curley, K.J., Kong, M.M., Alijaniaram, M., Ji, X., Nguyen, T., O'Dowd B, F., George, S.R., D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol. Pharmacol. 68:3 (2005), 5–578, 10.1124/mol.105.012229.
54. [54] Marcellino, D., Ferre, S., Casado, V., Cortes, A., Le Foll, B., Mazzola, C., Drago, F., Saur, O., Stark, H., Soriano, A., Barnes, C., Goldberg, S.R., Lluis, C., Fuxe, K., Franco, R., Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem. 283:38 (2008), 26016–26025, 10.1074/jbc.M710349200.
55. [55] Fiorentini, C., Busi, C., Gorruso, E., Gotti, C., Spano, P., Missale, C., Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 74:1 (2008), 59–69, 10.1124/mol.107.043885.
56. [56] Wang, M., Pei, L., Fletcher, P.J., Kapur, S., Seeman, P., Liu, F., Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. Mol. Brain, 3, 2010, 25, 10.1186/1756-6606-3-25.
57. [57] Strange, P.G., Oligomers of D2 dopamine receptors: evidence from ligand binding. J. Mol. Neurosci.: MN 26:2–3 (2005), 155–160, 10.1385/jmn:26:2-3:155.
58. [58] Maggio, R., Millan, M.J., Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr. Opin. Pharmacol. 10:1 (2010), 100–107, 10.1016/j.coph.2009.10.001.
59. [59] Gonzalez, S., Rangel-Barajas, C., Peper, M., Lorenzo, R., Moreno, E., Ciruela, F., Borycz, J., Ortiz, J., Lluis, C., Franco, R., McCormick, P.J., Volkow, N.D., Rubinstein, M., Floran, B., Ferre, S., Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Mol. Psychiatry 17:6 (2012), 650–662, 10.1038/mp.2011.93.
60. [60] Hillion, J., Canals, M., Torvinen, M., Casado, V., Scott, R., Terasmaa, A., Hansson, A., Watson, S., Olah, M.E., Mallol, J., Canela, E.I., Zoli, M., Agnati, L.F., Ibanez, C.F., Lluis, C., Franco, R., Ferre, S., Fuxe, K., Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277:20 (2002), 18091–18097, 10.1074/jbc.m107731200.
61. [61] Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S.R., Neve, K., Fuxe, K., Agnati, L.F., Woods, A.S., Ferre, S., Lluis, C., Bouvier, M., Franco, R., Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278:47 (2003), 46741–46749, 10.1074/jbc.m306451200.
62. [62] Kearn, C.S., Blake-Palmer, K., Daniel, E., Mackie, K., Glass, M., Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol. Pharmacol. 67:5 (2005), 1697–1704, 10.1124/mol.104.006882.
63. [63] Marcellino, D., Carriba, P., Filip, M., Borgkvist, A., Frankowska, M., Bellido, I., Tanganelli, S., Muller, C.E., Fisone, G., Lluis, C., Agnati, L.F., Franco, R., Fuxe, K., Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54:5 (2008), 815–823, 10.1016/j.neuropharm.2007.12.011.
64. [64] Baragli, A., Alturaihi, H., Watt, H.L., Abdallah, A., Kumar, U., Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19:11 (2007), 2304–2316, 10.1016/j.cellsig.2007.07.007.
65. [65] Rocheville, M., Lange, D.C., Kumar, U., Patel, S.C., Patel, R.C., Patel, Y.C., Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Sci. (New York NY) 288:5463 (2000), 154–157.
66. [66] Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., Roux, T., Bazin, H., Bourrier, E., Lamarque, L., Breton, C., Rives, M.L., Newman, A., Javitch, J., Trinquet, E., Manning, M., Pin, J.P., Mouillac, B., Durroux, T., Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6:8 (2010), 587–594.
67. [67] Yoshioka, K., Saitoh, O., Nakata, H., Heteromeric association creates a P2Y-like adenosine receptor. Proc. Natl. Acad. Sci. U. S. A. 98:13 (2001), 7617–7622, 10.1073/pnas.121587098.
68. [68] Yoshioka, K., Hosoda, R., Kuroda, Y., Nakata, H., Hetero-oligomerization of adenosine A1 receptors with P2Y1 receptors in rat brains. FEBS Lett. 531:2 (2002), 299–303.
69. [69] Nakata, H., Yoshioka, K., Kamiya, T., Tsuga, H., Oyanagi, K., Functions of heteromeric association between adenosine and P2Y receptors. J. Mole. Neurosci.: MN 26:2–3 (2005), 233–238, 10.1385/jmn:26:2-3:233.
70. [70] Wright, S.R., Zanos, P., Georgiou, P., Yoo, J.H., Ledent, C., Hourani, S.M., Kitchen, I., Winsky-Sommerer, R., Bailey, A., A critical role of striatal A2A R-mGlu5 R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine. Addict. Biol. 21:4 (2016), 811–825, 10.1111/adb.12259.
71. [71] Ecke, D., Hanck, T., Tulapurkar, M.E., Schafer, R., Kassack, M., Stricker, R., Reiser, G., Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. Biochem. J. 409:1 (2008), 107–116, 10.1042/bj20070671.
72. [72] Kleinau, G., Muller, A., Biebermann, H., Oligomerization of GPCRs involved in endocrine regulation. J. Mol. Endocrinol. 57:1 (2016), R59–R80, 10.1530/jme-16-0049.
73. [73] Kroeger, K.M., Hanyaloglu, A.C., Seeber, R.M., Miles, L.E., Eidne, K.A., Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer. J. Biol. Chem. 276:16 (2001), 12736–12743, 10.1074/jbc.m011311200.
74. [74] Song, G.J., Hinkle, P.M., Regulated dimerization of the thyrotropin-releasing hormone receptor affects receptor trafficking but not signaling. Mol. Endocrinol. (Baltimore, Md) 19:11 (2005), 2859–2870, 10.1210/me.2005-0133.
75. [75] Zhu, C.C., Cook, L.B., Hinkle, P.M., Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation. J. Biol. Chem. 277:31 (2002), 28228–28237, 10.1074/jbc.m204221200.
76. [76] Urizar, E., Montanelli, L., Loy, T., Bonomi, M., Swillens, S., Gales, C., Bouvier, M., Smits, G., Vassart, G., Costagliola, S., Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. 24:11 (2005), 1954–1964, 10.1038/sj.emboj.7600686.
77. [77] Mazurkiewicz, J.E., Herrick-Davis, K., Barroso, M., Ulloa-Aguirre, A., Lindau-Shepard, B., Thomas, R.M., Dias, J.A., Single-molecule analyses of fully functional fluorescent protein-tagged follitropin receptor reveal homodimerization and specific heterodimerization with lutropin receptor. Biol. Reprod., 92(4), 2015, 100, 10.1095/biolreprod.114.125781.
78. [78] Feng, X., Zhang, M., Guan, R., Segaloff, D.L., Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology 154:10 (2013), 3925–3930, 10.1210/en.2013-1407.
79. [79] Muller, T.D., Muller, A., Yi, C.X., Habegger, K.M., Meyer, C.W., Gaylinn, B.D., Finan, B., Heppner, K., Trivedi, C., Bielohuby, M., Abplanalp, W., Meyer, F., Piechowski, C.L., Pratzka, J., Stemmer, K., Holland, J., Hembree, J., Bhardwaj, N., Raver, C., Ottaway, N., Krishna, R., Sah, R., Sallee, F.R., Woods, S.C., Perez-Tilve, D., Bidlingmaier, M., Thorner, M.O., Krude, H., Smiley, D., DiMarchi, R., Hofmann, S., Pfluger, P.T., Kleinau, G., Biebermann, H., Tschop, M.H., The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. Nat. Commun., 4, 2013, 1968, 10.1038/ncomms2968.
80. [80] Rediger, A., Piechowski, C.L., Habegger, K., Gruters, A., Krude, H., Tschop, M.H., Kleinau, G., Biebermann, H., MC4R dimerization in the paraventricular nucleus and GHSR/MC3R heterodimerization in the arcuate nucleus: is there relevance for body weight regulation?. Neuroendocrinology 95:4 (2012), 277–288, 10.1159/000334903.
81. [81] Herrick-Davis, K., Grinde, E., Lindsley, T., Teitler, M., Mancia, F., Cowan, A., Mazurkiewicz, J.E., Native serotonin 5-HT2C receptors are expressed as homodimers on the apical surface of choroid plexus epithelial cells. Mol. Pharmacol. 87:4 (2015), 660–673.
82. [82] Perreault, M.L., Hasbi, A., Alijaniaram, M., Fan, T., Varghese, G., Fletcher, P.J., Seeman, P., O'Dowd, B.F., George, S.R., The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J. Biol. Chem. 285:47 (2010), 36625–36634.
83. [83] Agnati, L.F., Guidolin, D., Albertin, G., Trivello, E., Ciruela, F., Genedani, S., Tarakanov, A., Fuxe, K., An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors. J. Recept. Signal Transduct. Res. 30:5 (2010), 355–369, 10.3109/10799893.2010.487492.
84. [84] Cabello, N., Gandia, J., Bertarelli, D.C., Watanabe, M., Lluis, C., Franco, R., Ferre, S., Lujan, R., Ciruela, F., Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J. Neurochem. 109:5 (2009), 1497–1507, 10.1111/j.1471-4159.2009.06078.x.
85. [85] Ng, H.K., Chow, B.K., Oligomerization of family B GPCRs: exploration in inter-family oligomer formation. Front. Endocrinol., 6, 2015, 10, 10.3389/fendo.2015.00010.
86. [86] Ding, W.Q., Cheng, Z.J., McElhiney, J., Kuntz, S.M., Miller, L.J., Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res. 62:18 (2002), 5223–5229.
87. [87] Harikumar, K.G., Morfis, M.M., Lisenbee, C.S., Sexton, P.M., Miller, L.J., Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol. Pharmacol. 69:1 (2006), 363–373, 10.1124/mol.105.015776.
88. [88] Harikumar, K.G., Morfis, M.M., Sexton, P.M., Miller, L.J., Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J. Mol. Neurosci.: MN 36:1–3 (2008), 279–285, 10.1007/s12031-008-9060-z.
89. [89] Vrecl, M., Drinovec, L., Elling, C., Heding, A., Opsin oligomerization in a heterologous cell system. J. Recept. Signal. Transduct. Res. 26:5-6 (2006), 505–526, 10.1080/10799890600932253.
90. [90] Lee, V.H., Lee, L.T., Chu, J.Y., Lam, I.P., Siu, F.K., Vaudry, H., Chow, B.K., An indispensable role of secretin in mediating the osmoregulatory functions of angiotensin II. FASEB J. 24:12 (2010), 5024–5032, 10.1096/fj.10-165399.
91. [91] Borroto-Escuela, D.O., Brito, I., Romero-Fernandez, W., Di Palma, M., Oflijan, J., Skieterska, K., Duchou, J., Van Craenenbroeck, K., Suarez-Boomgaard, D., Rivera, A., Guidolin, D., Agnati, L.F., Fuxe, K., The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. Int. J. Mol. Sci. 15:5 (2014), 8570–8590, 10.3390/ijms15058570.
92. [92] Lefkowitz, R.J., Summary of Wenner-Gren international symposium receptor-receptor interactions among heptaspanning membrane receptors: from structure to function. J. Mol. Neurosc.: MN 26:2-3 (2005), 293–294, 10.1385/jmn:26:2-3:293.
93. [93] Agnati, L.F., Tarakanov, A.O., Ferre, S., Fuxe, K., Guidolin, D., Receptor-receptor interactions, receptor mosaics, and basic principles of molecular network organization: possible implications for drug development. J. Mol. Neurosci.: MN 26:2–3 (2005), 193–208, 10.1385/jmn:26:2-3:193.
94. [94] Agnati, L.F., Guidolin, D., Leo, G., Carone, C., Genedani, S., Fuxe, K., Receptor-receptor interactions: a novel concept in brain integration. Prog. Neurobiol. 90:2 (2010), 157–175, 10.1016/j.pneurobio.2009.10.004.
95. [95] Ahmad, R., Wojciech, S., Jockers, R., Hunting for the function of orphan GPCRs- beyond the search for the endogenous ligand. Br. J. Pharmacol. 172:13 (2015), 3212–3228.
96. [96] Orlandi, C., Cao, Y., Martemyanov, K.A., Orphan receptor GPR179 forms macromolecular complexes with components of metabotropic signaling cascade in retina ON-bipolar neurons. Invest. Ophthalmol. Vis. Sci. 54:10 (2013), 7153–7161.
97. [97] Levoye, A., Dam, J., Ayoub, M.A., Guillaume, J.L., Couturier, C., Delagrange, P., Jockers, R., The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 25:13 (2006), 3012–3023, 10.1038/sj.embor.7400838.
98. [98] Levoye, A., Dam, J., Ayoub, M.A., Guillaume, J.L., Jockers, R., Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep. 7:11 (2006), 1094–1098.
99. [99] Milasta, S., Pediani, J., Appelbe, S., Trim, S., Wyatt, M., Cox, P., Fidock, M., Milligan, G., Interactions between the Mas-related receptors MrgD and MrgE alter signalling and trafficking of MrgD. Mol. Pharmacol. 69:2 (2006), 479–491, 10.1124/mol.105.018788.
100. [100] Kern, A., Albarran-Zeckler, R., Walsh, H.E., Smith, R.G., Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73:2 (2012), 317–332.
101. [101] Schellekens, H., Dinan, T.G., Cryan, J.F., Taking two to tango: a role for ghrelin receptor heterodimerization in stress and reward. Front. Neurosci., 7(148), 2013.
102. [102] Park, S., Jiang, H., Zhang, H., Smith, R.G., Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release. Proc. Natl. Acad. Sci. U. S. A. 109:46 (2012), 19003–19008.
103. [103] Takahashi, K., Furukawa, C., Takano, A., Ishikawa, N., Kato, T., Hayama, S., Suzuki, C., Yasui, W., Inai, K., Sone, S., Ito, T., Nishimura, H., Tsuchiya, E., Nakamura, Y., Daigo, Y., The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66:19 (2006), 9408–9419, 10.1158/0008-5472.can-06-1349.
104. [104] Wertman, J., Dupre, D.J., G protein-coupled receptor dimers: look like their parents but act like teenagers!. J. Receptor Signal. Transduction Res. 33:3 (2013), 135–138, 10.3109/10799893.2012.759591.
105. [105] Salahpour, A., Angers, S., Mercier, J.F., Lagace, M., Marullo, S., Bouvier, M., Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J. Biol. Chem. 279:32 (2004), 33390–33397, 10.1074/jbc.M403363200.
106. [106] Van Craenenbroeck, K., Borroto-Escuela, D.O., Romero-Fernandez, W., Skieterska, K., Rondou, P., Lintermans, B., Vanhoenacker, P., Fuxe, K., Ciruela, F., Haegeman, G., Dopamine D4 receptor oligomerization–contribution to receptor biogenesis. FEBS J. 278:8 (2011), 1333–1344, 10.1111/j.1742-4658 1742-4658.2011.08052.x.
107. [107] Herrick-Davis, K., Weaver, B.A., Grinde, E., Mazurkiewicz, J.E., Serotonin 5-HT2C receptor homodimer biogenesis in the endoplasmic reticulum: real-time visualization with confocal fluorescence resonance energy transfer. J. Biol. Chem. 281:37 (2006), 27109–27116, 10.1074/jbc.M604390200.
108. [108] Abd Alla, J., Reeck, K., Langer, A., Streichert, T., Quitterer, U., Calreticulin enhances B2 bradykinin receptor maturation and heterodimerization. Biochem. Biophys. Res. Commun. 387:1 (2009), 186–190, 10.1016/j.bbrc.2009.07.011.
109. [109] Abd Alla, J., Pohl, A., Reeck, K., Streichert, T., Quitterer, U., Establishment of an in vivo model facilitates B2 receptor protein maturation and heterodimerization. Integr. Biol.: Quantitative Biosci. Nano Macro 2:4 (2010), 209–217, 10.1039/b922592g.
110. [110] Vilardaga, J.P., Agnati, L.F., Fuxe, K., Ciruela, F., G-protein-coupled receptor heteromer dynamics. J. Cell Sci. 123:Pt. 24 (2010), 4215–4220, 10.1242/jcs.063354.
111. [111] Decaillot, F.M., Rozenfeld, R., Gupta, A., Devi, L.A., Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc. Natl. Acad. Sci. U. S. A. 105:41 (2008), 16045–16050, 10.1073/pnas.0804106105.
112. [112] Agnati, L.F., Leo, G., Genedani, S., Andreoli, N., Marcellino, D., Woods, A., Piron, L., Guidolin, D., Fuxe, K., Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains. Brain Res. Rev. 58:2 (2008), 459–474, 10.1016/j.brainresrev.2007.10.003.
113. [113] Changeux, J.P., 50 years of allosteric interactions: the twists and turns of the models. Nat. Rev. Mol. Cell Biol. 14:12 (2013), 819–829, 10.1038/nrm3695.
114. [114] Huang, Y.J., Montelione, G.T., Structural biology: proteins flex to function. Nature 438:7064 (2005), 36–37, 10.1038/438036a.
115. [115] Tovo-Rodrigues, L., Roux, A., Hutz, M.H., Rohde, L.A., Woods, A.S., Functional characterization of G-protein-coupled receptors: a bioinformatics approach. Neuroscience 277 (2014), 764–779.
116. [116] Venkatakrishnan, A.J., Flock, T., Prado, D.E., Oates, M.E., Gough, J., Madan Babu, M., Structured and disordered facets of the GPCR fold. Curr. Opin. Struct. Biol. 27 (2014), 129–137, 10.1016/j.sbi.2014.08.002.
117. [117] Jaakola, V.P., Prilusky, J., Sussman, J.L., Goldman, A., G protein-coupled receptors show unusual patterns of intrinsic unfolding. Protein Eng. Des. Sel. 18:2 (2005), 103–110, 10.1093/protein/gzi004.
118. [118] Unal, H., Karnik, S.S., Domain coupling in GPCRs: the engine for induced conformational changes. Trends Pharmacol. Sci. 33:2 (2012), 79–88.
119. [119] Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S., Thian, F.S., Chae, P.S., Pardon, E., Calinski, D., Mathiesen, J.M., Shah, S.T., Lyons, J.A., Caffrey, M., Gellman, S.H., Steyaert, J., Skiniotis, G., Weis, W.I., Sunahara, R.K., Kobilka, B.K., Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477:7366 (2011), 549–555.
120. [120] Elgeti, M., Rose, A.S., Bartl, F.J., Hildebrand, P.W., Hofmann, K.P., Heck, M., Precision vs flexibility in GPCR signaling. J. Am. Chem. Soc. 135:33 (2013), 12305–12312, 10.1021/ja405133k.
121. [121] Boguth, C.A., Singh, P., Huang, C.C., Tesmer, J.J., Molecular basis for activation of G protein-coupled receptor kinases. EMBO J. 29:19 (2010), 3249–3259.
122. [122] Simpson, L.M., Taddese, B., Wall, I.D., Reynolds, C.A., Bioinformatics and molecular modelling approaches to GPCR oligomerization. Curr. Opin. Pharmacol. 10:1 (2010), 30–37, 10.1016/j.coph.2009.11.001.
123. [123] Jonas, K.C., Huhtaniemi, I., Hanyaloglu, A.C., Single-molecule resolution of G protein-coupled receptor (GPCR) complexes. Methods Cell Biol. 132 (2016), 55–72, 10.1016/bs.mcb.2015.11.005.
124. [124] Liang, Y., Fotiadis, D., Filipek, S., Saperstein, D.A., Palczewski, K., Engel, A., Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 278:24 (2003), 21655–21662, 10.1074/jbc.m302536200.
125. [125] Ruprecht, J.J., Mielke, T., Vogel, R., Villa, C., Schertler, G.F., Electron crystallography reveals the structure of metarhodopsin I. EMBO J. 23:18 (2004), 3609–3620.
126. [126] Salom, D., Le Trong, I., Pohl, E., Ballesteros, J.A., Stenkamp, R.E., Palczewski, K., Lodowski, D.T., Improvements in G protein-coupled receptor purification yield light stable rhodopsin crystals. J. Struct. Biol. 156:3 (2006), 497–504, 10.1016/j.jsb.2006.05.003.
127. [127] Lodowski, D.T., Salom, D., Le Trong, I., Teller, D.C., Ballesteros, J.A., Palczewski, K., Stenkamp, R.E., Crystal packing analysis of Rhodopsin crystals. J. Struct. Biol. 158:3 (2007), 455–462.
128. [128] Salom, D., Padayatti, P.S., Palczewski, K., Crystallization of G protein-coupled receptors. Methods Cell Biol. 117 (2013), 451–468.
129. [129] Lee, S.P., O'Dowd, B.F., Rajaram, R.D., Nguyen, T., George, S.R., D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. Biochemistry 42:37 (2003), 11023–11031, 10.1021/bi0345539.
130. [130] Kaczor, A.A., Jorg, M., Capuano, B., The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics. J. Mol. Model., 22(9), 2016, 203.
131. [131] Huang, J., Chen, S., Zhang, J.J., Huang, X.Y., Crystal structure of oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. 20:4 (2013), 419–425.
132. [132] Filizola, M., Weinstein, H., The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J. 272:12 (2005), 2926–2938, 10.1111/j.1742-4658.2005.04730.x.
133. [133] Huang, W., Manglik, A., Venkatakrishnan, A.J., Laeremans, T., Feinberg, E.N., Sanborn, A.L., Kato, H.E., Livingston, K.E., Thorsen, T.S., Kling, R.C., Granier, S., Gmeiner, P., Husbands, S.M., Traynor, J.R., Weis, W.I., Steyaert, J., Dror, R.O., Kobilka, B.K., Structural insights into micro-opioid receptor activation. Nature 524:7565 (2015), 315–321.
134. [134] Marino, K.A., Prada-Gracia, D., Provasi, D., Filizola, M., Impact of lipid composition and receptor conformation on the spatio-temporal organization of mu-opioid receptors in a multi-component plasma membrane model. PLoS Comput. Biol., 12(12), 2016, e1005240.
135. [135] Johnston, J.M., Filizola, M., Differential stability of the crystallographic interfaces of mu- and kappa-opioid receptors. PLoS One, 9(2), 2014, e90694.
136. [136] Yoshikawa, Y., Kobayashi, K., Oishi, S., Fujii, N., Furuya, T., Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. Bioorg. Med. Chem. Lett. 22:6 (2012), 2146–2150, 10.1016/j.bmcl.2012.01.134.
137. [137] Qin, L., Kufareva, I., Holden, L.G., Wang, C., Zheng, Y., Zhao, C., Fenalti, G., Wu, H., Han, G.W., Cherezov, V., Abagyan, R., Stevens, R.C., Handel, T.M., Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Sci. (New York NY) 347:6226 (2015), 1117–1122.
138. [138] Stephens, B., Handel, T.M., Chemokine receptor oligomerization and allostery. Prog. Mol. Biol. Transl. Sci. 115 (2013), 375–420.
139. [139] Pluhackova, K., Gahbauer, S., Kranz, F., Wassenaar, T.A., Bockmann, R.A., Dynamic cholesterol-conditioned dimerization of the G protein coupled chemokine receptor type 4. PLoS Comput. Biol., 12(11), 2016, e1005169.
140. [140] Wang, J., He, L., Combs, C.A., Roderiquez, G., Norcross, M.A., Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions. Mol. Cancer Ther. 5:10 (2006), 2474–2483, 10.1158/1535-7163 (mct-05-0261).
141. [141] Gorinski, N., Kowalsman, N., Renner, U., Wirth, A., Reinartz, M.T., Seifert, R., Zeug, A., Ponimaskin, E., Niv, M.Y., Computational and experimental analysis of the transmembrane domain 4/5 dimerization interface of the serotonin 5-HT(1A) receptor. Mol. Pharmacol. 82:3 (2012), 448–463, 10.1124/mol.112.079137.
142. [142] Jafurulla, M., Chattopadhyay, A., Application of Quantitative Fluorescence Microscopic Approaches to Monitor Organization and Dynamics of the Serotonin1A Receptor. Mély, Y., Duportail, G., (eds.) Fluorescent Methods to Study Biological Membranes, 2013, Springer Berlin Heidelberg, Berlin, Heidelberg, 417–437, 10.1007/4243_2012_58.
143. [143] Jafurulla, M., Tiwari, S., Chattopadhyay, A., Identification of cholesterol recognition amino acid consensus (CRAC) motif in G-protein coupled receptors. Biochem. Biophys. Res. Commun. 404:1 (2011), 569–573, 10.1016/j.bbrc.2010.12.031.
144. [144] Liu, W., Chun, E., Thompson, A.A., Chubukov, P., Xu, F., Katritch, V., Han, G.W., Roth, C.B., Heitman LH, L.H., I.J, A.P., Cherezov, V., Stevens, R.C., Structural basis for allosteric regulation of GPCRs by sodium ions. Sci.(New York, NY 337:6091 (2012), 232–236.
145. [145] Fanelli, F., Felline, A., Dimerization and ligand binding affect the structure network of A(2A) adenosine receptor. Biochim. Biophys. Acta 1808:5 (2011), 1256–1266, 10.1016/j.bbamem.2010.08.006.
146. [146] Burgueno, J., Blake, D.J., Benson, M.A., Tinsley, C.L., Esapa, C.T., Canela, E.I., Penela, P., Mallol, J., Mayor, F. Jr., Lluis, C., Franco, R., Ciruela, F., The adenosine A2A receptor interacts with the actin-binding protein alpha-actinin. J. Biol. Chem. 278:39 (2003), 37545–37552, 10.1074/jbc.M302809200.
147. [147] Schonenbach, N.S., Rieth, M.D., Han, S., O'Malley, M.A., Adenosine A2a receptors form distinct oligomers in protein detergent complexes. FEBS Lett. 590:18 (2016), 3295–3306.
148. [148] Ciruela, F., Burgueno, J., Casado, V., Canals, M., Marcellino, D., Goldberg, S.R., Bader, M., Fuxe, K., Agnati, L.F., Lluis, C., Franco, R., Ferre, S., Woods, A.S., Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem. 76:18 (2004), 5354–5363, 10.1021/ac049295f.
149. [149] Zhang, D., Gao, Z.G., Zhang, K., Kiselev, E., Crane, S., Wang, J., Paoletta, S., Yi, C., Ma, L., Zhang, W., Han, G.W., Liu, H., Cherezov, V., Katritch, V., Jiang, H., Stevens, R.C., Jacobson, K.A., Zhao, Q., Wu, B., Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520:7547 (2015), 317–321.
150. [150] Zhang, J., Zhang, K., Gao, Z.G., Paoletta, S., Zhang, D., Han, G.W., Li, T., Ma, L., Zhang, W., Muller, C.E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K.A., Stevens, R.C., Wu, B., Zhao, Q., Agonist-bound structure of the human P2Y12 receptor. Nature 509:7498 (2014), 119–122.
151. [151] Casado-Anguera, V., Bonaventura, J., Moreno, E., Navarro, G., Cortes, A., Ferre, S., Casado, V., Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex. Biochem. Soc. Trans. 44:2 (2016), 595–600, 10.1042/bst20150276.
152. [152] Guitart, X., Navarro, G., Moreno, E., Yano, H., Cai, N.S., Sanchez-Soto, M., Kumar-Barodia, S., Naidu, Y.T., Mallol, J., Cortes, A., Lluis, C., Canela, E.I., Casado, V., McCormick, P.J., Ferre, S., Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer. Mol. Pharmacol. 86:4 (2014), 417–429, 10.1124/mol.114.093096.
153. [153] Vinals, X., Moreno, E., Lanfumey, L., Cordomi, A., Pastor, A., de La Torre, R., Gasperini, P., Navarro, G., Howell, L.A., Pardo, L., Lluis, C., Canela, E.I., McCormick, P.J., Maldonado, R., Robledo, P., Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLoS Biol., 13(7), 2015, e1002194, 10.1371/journal.pbio.1002194.
154. [154] Navarro, G., Quiroz, C., Moreno-Delgado, D., Sierakowiak, A., McDowell, K., Moreno, E., Rea, W., Cai, N.S., Aguinaga, D., Howell, L.A., Hausch, F., Cortes, A., Mallol, J., Casado, V., Lluis, C., Canela, E.I., Ferre, S., McCormick, P.J., Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine. J. Neurosci. Off. Soc. Neurosci. 35:17 (2015), 6639–6653, 10.1523/jneurosci.4364-14.2015.
155. [155] Geng, Y., Bush, M., Mosyak, L., Wang, F., Fan, Q.R., Structural mechanism of ligand activation in human GABA(B) receptor. Nature 504:7479 (2013), 254–259.
156. [156] Wu, H., Wang, C., Gregory, K.J., Han, G.W., Cho, H.P., Xia, Y., Niswender, C.M., Katritch, V., Meiler, J., Cherezov, V., Conn, P.J., Stevens, R.C., Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Sci. (New York NY) 344:6179 (2014), 58–64.
157. [157] Scarselli, M., Annibale, P., Gerace, C., Radenovic, A., Enlightening G-protein-coupled receptors on the plasma membrane using super-resolution photoactivated localization microscopy. Biochem. Soc. Trans. 41:1 (2013), 191–196, 10.1042/bst20120250.
158. [158] Scarselli, M., Annibale, P., McCormick, P.J., Kolachalam, S., Aringhieri, S., Radenovic, A., Corsini, G.U., Maggio, R., Revealing G-protein-coupled receptor oligomerization at the single-molecule level through a nanoscopic lens: methods, dynamics and biological function. FEBS J. 283:7 (2016), 1197–1217, 10.1111/febs.13577.
159. [159] Navarro, G., Ferre, S., Cordomi, A., Moreno, E., Mallol, J., Casado, V., Cortes, A., Hoffmann, H., Ortiz, J., Canela, E.I., Lluis, C., Pardo, L., Franco, R., Woods, A.S., Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J. Biol. Chem. 285:35 (2010), 27346–27359.
160. [160] Navarro, G., Cordomi, A., Zelman-Femiak, M., Brugarolas, M., Moreno, E., Aguinaga, D., Perez-Benito, L., Cortes, A., Casado, V., Mallol, J., Canela, E.I., Lluis, C., Pardo, L., Garcia-Saez, A.J., McCormick, P.J., Franco, R., Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs. BMC Biol., 14, 2016, 26.
161. [161] Jonas, K.C., Fanelli, F., Huhtaniemi, I.T., Hanyaloglu, A.C., Single molecule analysis of functionally asymmetric G protein-coupled receptor (GPCR) oligomers reveals diverse spatial and structural assemblies. J. Biol. Chem. 290:7 (2015), 3875–3892, 10.1074/jbc.m114.622498.
162. [162] Marsango, S., Caltabiano, G., Pou, C., Varela Liste, M.J., Milligan, G., Analysis of human dopamine D3 receptor quaternary structure. J. Biol. Chem. 290:24 (2015), 15146–15162.
163. [163] Pediani, J.D., Ward, R.J., Godin, A.G., Marsango, S., Milligan, G., Dynamic regulation of quaternary organization of the M1 muscarinic receptor by subtype-selective antagonist drugs. J. Biol. Chem. 291:25 (2016), 13132–13146.
164. [164] Mishra, A.K., Gragg, M., Stoneman, M.R., Biener, G., Oliver, J.A., Miszta, P., Filipek, S., Raicu, V., Park, P.S., Quaternary structures of opsin in live cells revealed by FRET spectrometry. Biochem. J. 473:21 (2016), 3819–3836.
165. [165] Jastrzebska, B., Comar, W.D., Kaliszewski, M.J., Skinner, K.C., Torcasio, M.H., Esway, A.S., Jin, H., Palczewski, K., Smith, A.W., A G protein-coupled receptor dimerization interface in human cone opsins. Biochemistry, 2016, 61–72, 10.1021/acs.biochem.6b00877.
166. [166] Schmidt, H.R., Zheng, S., Gurpinar, E., Koehl, A., Manglik, A., Kruse, A.C., Crystal structure of the human sigma1 receptor. Nature 532:7600 (2016), 527–530, 10.1038/nature17391.
167. [167] Guidolin, D., Ciruela, F., Genedani, S., Guescini, M., Tortorella, C., Albertin, G., Fuxe, K., Agnati, L.F., Bioinformatics and mathematical modelling in the study of receptor-receptor interactions and receptor oligomerization: focus on adenosine receptors. Biochim. Biophys. Acta 1808:5 (2011), 1267–1283, 10.1016/j.bbamem.2010.09.022.
168. [168] Gouldson, P.R., Reynolds, C.A., Simulations on dimeric peptides: evidence for domain swapping in G-protein-coupled receptors?. Biochem. Soc. Trans. 25:3 (1997), 1066–1071.
169. [169] Gouldson, P.R., Higgs, C., Smith, R.E., Dean, M.K., Gkoutos, G.V., Reynolds, C.A., Dimerization and domain swapping in G-protein-coupled receptors: a computational study. Neuropsychopharmacology 23:Suppl. (4) (2000), S60–S77, 10.1016/s0893-133x(00)00153-6.
170. [170] Gouldson, P.R., Snell, C.R., Bywater, R.P., Higgs, C., Reynolds, C.A., Domain swapping in G-protein coupled receptor dimers. Protein Eng. 11:12 (1998), 1181–1193.
171. [171] Kamal, M., Maurice, P., Jockers, R., Expanding the concept of G protein-coupled receptor (GPCR) dimer asymmetry towards GPCR-interacting proteins. Pharmaceuticals 4:12 (2011), 273–284, 10.3390/ph4020273.
172. [172] White, J.F., Grodnitzky, J., Louis, J.M., Trinh, L.B., Shiloach, J., Gutierrez, J., Northup, J.K., Grisshammer, R., Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc. Natl. Acad. Sci. U. S. A. 104:29 (2007), 12199–12204, 10.1073/pnas.0705312104.
173. [173] Damian, M., Martin, A., Mesnier, D., Pin, J.P., Baneres, J.L., Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 25:24 (2006), 5693–5702, 10.1038/sj.emboj.7601449.
174. [174] Damian, M., Mary, S., Martin, A., Pin, J.P., Baneres, J.L., G protein activation by the leukotriene B4 receptor dimer. Evidence for an absence of trans-activation. J. Biol. Chem. 283:30 (2008), 21084–21092, 10.1074/jbc.M710419200.
175. [175] Galvez, T., Duthey, B., Kniazeff, J., Blahos, J., Rovelli, G., Bettler, B., Prezeau, L., Pin, J.P., Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J. 20:9 (2001), 2152–2159, 10.1093/emboj/20.9.2152.
176. [176] Goudet, C., Kniazeff, J., Hlavackova, V., Malhaire, F., Maurel, D., Acher, F., Blahos, J., Prezeau, L., Pin, J.P., Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J. Biol. Chem. 280:26 (2005), 24380–24385, 10.1074/jbc.M502642200.
177. [177] Duthey, B., Caudron, S., Perroy, J., Bettler, B., Fagni, L., Pin, J.P., Prezeau, L., A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. J. Biol. Chem. 277:5 (2002), 3236–3241, 10.1074/jbc.M108900200.
178. [178] Hlavackova, V., Goudet, C., Kniazeff, J., Zikova, A., Maurel, D., Vol, C., Trojanova, J., Prezeau, L., Pin, J.P., Blahos, J., Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 24:3 (2005), 499–509, 10.1038/sj.emboj.7600557.
179. [179] Agnati, L.F., Guidolin, D., Vilardaga, J.P., Ciruela, F., Fuxe, K., On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers. J. Recept. Signal Transduct. Res. 30:5 (2010), 287–303, 10.3109/10799891003786226.
180. [180] Agnati, L.F., Fuxe, K., Ferre, S., How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends Biochem. Sci. 30:4 (2005), 188–193, 10.1016/j.tibs.2005.02.010.
181. [181] Guo, W., Urizar, E., Kralikova, M., Mobarec, J.C., Shi, L., Filizola, M., Javitch, J.A., Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J. 27:17 (2008), 2293–2304.
182. [182] Gandia, J., Galino, J., Amaral, O.B., Soriano, A., Lluis, C., Franco, R., Ciruela, F., Detection of higher-order G protein-coupled receptor oligomers by a combined BRET-BiFC technique. FEBS Lett. 582:20 (2008), 2979–2984, 10.1016/j.febslet.2008.07.045.
183. [183] Park, P.S., Wells, J.W., Oligomeric potential of the M2 muscarinic cholinergic receptor. J. Neurochem. 90:3 (2004), 537–548, 10.1111/j.1471-4159.2004.02536.x.
184. [184] Carriba, P., Navarro, G., Ciruela, F., Ferre, S., Casado, V., Agnati, L., Cortes, A., Mallol, J., Fuxe, K., Canela, E.I., Lluis, C., Franco, R., Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods 5:8 (2008), 727–733, 10.1038/nmeth.1229.
185. [185] Vidi, P.A., Chemel, B.R., Hu, C.D., Watts, V.J., Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells. Mol. Pharmacol. 74:3 (2008), 544–551, 10.1124/mol.108.047472.
186. [186] Agnati, L.F., Fuxe, K., Zoli, M., Rondanini, C., Ogren, S.O., New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med. Biol. 60:4 (1982), 183–190.
187. [187] Agnati, L.F., Ferre, S., Leo, G., Lluis, C., Canela, E.I., Franco, R., Fuxe, K., On the molecular basis of the receptor mosaic hypothesis of the engram. Cell. Mol. Neurobiol. 24:4 (2004), 501–516.
188. [188] Agnati, L.F., Franzen, O., Ferre, S., Leo, G., Franco, R., Fuxe, K., Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. J. Neural Transm. Suppl. 65 (2003), 1–28.
189. [189] Fuxe, K., Marcellino, D., Guidolin, D., Woods, A.S., Agnati, L.F., Heterodimers and receptor mosaics of different types of G-protein-coupled receptors. Physiol. (Bethesda, Md) 23 (2008), 322–332, 10.1152/physiol.00028.2008.
190. [190] Kenakin, T.P., Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 8:8 (2009), 617–626, 10.1038/nrd2838.
191. [191] Nimchinsky, E.A., Hof, P.R., Janssen, W.G., Morrison, J.H., Schmauss, C., Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J. Biol. Chem. 272:46 (1997), 29229–29237.
192. [192] Elmhurst, J.L., Xie, Z., O'Dowd, B.F., George, S.R., The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Brain Res. Mol. Brain Res. 80:1 (2000), 63–74.
193. [193] Navarro, G., Carriba, P., Gandia, J., Ciruela, F., Casado, V., Cortes, A., Mallol, J., Canela, E.I., Lluis, C., Franco, R., Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Sci. World J. 8 (2008), 1088–1097, 10.1100/tsw.2008.136.
194. [194] Fung, J.J., Deupi, X., Pardo, L., Yao, X.J., Velez-Ruiz, G.A., Devree, B.T., Sunahara, R.K., Kobilka, B.K., Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer. EMBO J. 28:21 (2009), 3315–3328.
195. [195] Mansoor, S.E., Palczewski, K., Farrens, D.L., Rhodopsin self-associates in asolectin liposomes. Proc. Natl. Acad. Sci. U. S. A. 103:9 (2006), 3060–3065.
196. [196] Harding, P.J., Attrill, H., Boehringer, J., Ross, S., Wadhams, G.H., Smith, E., Armitage, J.P., Watts, A., Constitutive dimerization of the G-protein coupled receptor, neurotensin receptor 1, reconstituted into phospholipid bilayers. Biophys. J. 96:3 (2009), 964–973.
197. [197] Ma, A.W., Redka, D.S., Pisterzi, L.F., Angers, S., Wells, J.W., Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles. Biochemistry 46:26 (2007), 7907–7927, 10.1021/bi6026105.
198. [198] Sohy, D., Yano, H., de Nadai, P., Urizar, E., Guillabert, A., Javitch, J.A., Parmentier, M., Springael, J.Y., Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of selective antagonists. J. Biol. Chem. 284:45 (2009), 31270–31279.
199. [199] Sohy, D., Parmentier, M., Springael, J.Y., Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem. 282:41 (2007), 30062–30069, 10.1074/jbc.m705302200.
200. [200] Agnati, L.F., Baluska, F., Barlow, P.W., Guidolin, D., Mosaic, self-similarity logic, and biological attraction principles: three explanatory instruments in biology. Commun. Integr. Biol. 2:6 (2009), 552–563.
201. [201] Fuxe, K., Marcellino, D., Rivera, A., Diaz-Cabiale, Z., Filip, M., Gago, B., Roberts, D.C., Langel, U., Genedani, S., Ferraro, L., de la Calle, A., Narvaez, J., Tanganelli, S., Woods, A., Agnati, L.F., Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev. 58:2 (2008), 415–452, 10.1016/j.brainresrev.2007.11.007.
202. [202] Agnati, L.F., Guidolin, D., Carone, C., Dam, M., Genedani, S., Fuxe, K., Understanding neuronal molecular networks builds on neuronal cellular network architecture. Brain Res. Rev. 58:2 (2008), 379–399, 10.1016/j.brainresrev.2007.11.002.
203. [203] Tsai, C.J., del Sol, A., Nussinov, R., Allostery: absence of a change in shape does not imply that allostery is not at play. J. Mol. Biol. 378:1 (2008), 1–11, 10.1016/j.jmb.2008.02.034.
204. [204] Gunasekaran, K., Ma, B., Nussinov, R., Is allostery an intrinsic property of all dynamic proteins?. Proteins 57:3 (2004), 433–443, 10.1002/prot.20232.
205. [205] Del Sol, A., Arauzo-Bravo, M.J., Amoros, D., Nussinov, R., Modular architecture of protein structures and allosteric communications: potential implications for signaling proteins and regulatory linkages. Genome Biol., 8(5), 2007, R92, 10.1186/gb-2007-8-5-r92.
206. [206] Agnati, L.F., Tarakanov, A.O., Guidolin, D., A simple mathematical model of cooperativity in receptor mosaics based on the symmetry rule. Biosystems 80:2 (2005), 165–173, 10.1016/j.biosystems.2004.11.004.
207. [207] Agnati, L.F., Guidolin, D., Leo, G., Fuxe, K., A boolean network modelling of receptor mosaics relevance of topology and cooperativity. J. Neural. Transm. (Vienna) 114:1 (2007), 77–92, 10.1007/s00702-006-0567-6.
208. [208] Francesco, A.L., Kjell, F., Amina, W., Susanna, G., Diego, G., Theoretical considerations on the topological organization of receptor mosaics. Curr. Protein Pept. Sci. 10:6 (2009), 559–569.
209. [209] Ferguson, S.S., Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol. Sci. 28:4 (2007), 173–179, 10.1016/j.tips.2007.02.008.
210. [210] Maurice, P., Daulat, A.M., Turecek, R., Ivankova-Susankova, K., Zamponi, F., Kamal, M., Clement, N., Guillaume, J.L., Bettler, B., Gales, C., Delagrange, P., Jockers, R., Molecular organization and dynamics of the melatonin MT(1) receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling. EMBO J. 29:21 (2010), 3646–3659.
211. [211] Maurice, P., Kamal, M., Jockers, R., Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol. Sci. 32:9 (2011), 514–520, 10.1016/j.tips.2011.05.006.
212. [212] Fenton, A.W., Allostery: an illustrated definition for the ‘second secret of life'. Trends Biochem. Sci. 33:9 (2008), 420–425.
213. [213] Changeux, J.P., The concept of allosteric interaction and its consequences for the chemistry of the brain. J. Biol. Chem. 288:38 (2013), 26969–26986.
214. [214] Changeux, J.P., Christopoulos, A., Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166:5 (2016), 1084–1102, 10.1016/j.cell.2016.08.015.
215. [215] Monod, J., Wyman, J., Changeux, J.P., On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12 (1965), 88–118.
216. [216] Azdad, K., Gall, D., Woods, A.S., Ledent, C., Ferre, S., Schiffmann, S.N., Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34:4 (2009), 972–986, 10.1038/npp.2008.144.
217. [217] Bonaventura, J., Navarro, G., Casado-Anguera, V., Azdad, K., Rea, W., Moreno, E., Brugarolas, M., Mallol, J., Canela, E.I., Lluis, C., Cortes, A., Volkow, N.D., Schiffmann, S.N., Ferre, S., Casado, V., Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. Proc. Natl. Acad. Sci. U. S. A. 112:27 (2015), E3609–E3618, 10.1073/pnas.1507704112.
218. [218] El-Asmar, L., Springael, J.Y., Ballet, S., Andrieu, E.U., Vassart, G., Parmentier, M., Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 67:2 (2005), 460–469, 10.1124/mol.104.003624.
219. [219] Barki-Harrington, L., Luttrell, L.M., Rockman, H.A., Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108:13 (2003), 1611–1618, 10.1161/01. cir.0000092166.30360.78.
220. [220] Szidonya, L., Cserzo, M., Hunyady, L., Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. J. Endocrinol. 196:3 (2008), 435–453, 10.1677/joe-07-0573.
221. [221] Redka, D.S., Morizumi, T., Elmslie, G., Paranthaman, P., Shivnaraine, R.V., Ellis, J., Ernst, O.P., Wells, J.W., Coupling of g proteins to reconstituted monomers and tetramers of the M2 muscarinic receptor. J. Biol. Chem. 289:35 (2014), 24347–24365.
222. [222] Shivnaraine, R.V., Kelly, B., Sankar, K.S., Redka, D.S., Han, Y.R., Huang, F., Elmslie, G., Pinto, D., Li, Y., Rocheleau, J.V., Gradinaru, C.C., Ellis, J., Wells, J.W., Allosteric modulation in monomers and oligomers of a G protein-coupled receptor. Elife, 5, 2016.
223. [223] Ferre, S., Bonaventura, J., Tomasi, D., Navarro, G., Moreno, E., Cortes, A., Lluis, C., Casado, V., Volkow, N.D., Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer. Neuropharmacology 104 (2016), 154–160, 10.1016/j.neuropharm.2015.05.028.
224. [224] Lee, S.P., So, C.H., Rashid, A.J., Varghese, G., Cheng, R., Lanca, A.J., O'Dowd, B.F., George, S.R., Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 279:34 (2004), 35671–35678, 10.1074/jbc.m401923200.
225. [225] Gonzalez-Maeso, J., Weisstaub, N.V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., Sealfon, S.C., Gingrich, J.A., Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:3 (2007), 439–452, 10.1016/j.neuron.2007.01.008.
226. [226] Gonzalez-Maeso, J., Ang, R.L., Yuen, T., Chan, P., Weisstaub, N.V., Lopez-Gimenez, J.F., Zhou, M., Okawa, Y., Callado, L.F., Milligan, G., Gingrich, J.A., Filizola, M., Meana, J.J., Sealfon, S.C., Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:7183 (2008), 93–97, 10.1038/nature06612.
227. [227] Han, Y., Moreira, I.S., Urizar, E., Weinstein, H., Javitch, J.A., Allosteric communication between protomers of dopamine class a GPCR dimers modulates activation. Nat. Chem. Biol. 5:9 (2009), 688–695.
228. [228] Cordomi, A., Navarro, G., Aymerich, M.S., Franco, R., Structures for G-protein-coupled receptor tetramers in complex with G proteins. Trends Biochem. Sci. 40:10 (2015), 548–551, 10.1016/j.tibs.2015.07.007.
229. [229] Cristovao-Ferreira, S., Navarro, G., Brugarolas, M., Perez-Capote, K., Vaz, S.H., Fattorini, G., Conti, F., Lluis, C., Ribeiro, J.A., McCormick, P.J., Casado, V., Franco, R., Sebastiao, A.M., A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Purinergic Signal. 9:3 (2013), 433–449.
230. [230] George, S.R., Fan, T., Xie, Z., Tse, R., Tam, V., Varghese O'Dowd, G.B.F., Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275:34 (2000), 26128–26135, 10.1074/jbc.M000345200.
231. [231] Rozenfeld, R., Devi, L.A., Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J. 21:10 (2007), 2455–2465.
232. [232] Hilairet, S., Bouaboula, M., Carriere, D., Le Fur, G., Casellas, P., Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J. Biol. Chem. 278:26 (2003), 23731–23737, 10.1074/jbc.M212369200.
233. [233] Liu, H., Tian, Y., Ji, B., Lu, H., Xin, Q., Jiang, Y., Ding, L., Zhang, J., Chen, J., Bai, B., Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel beta-arrestin-2-biased pathway. Biochim. Biophys. Acta 1863:11 (2016), 2719–2738, 10.1016/j.bbamcr.2016.07.009.
234. [234] Borroto-Escuela, D.O., Narvaez, M., Marcellino, D., Parrado, C., Narvaez, J.A., Tarakanov, A.O., Agnati, L.F., Diaz-Cabiale, Z., Fuxe, K., Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem. Biophys. Res. Commun. 393:4 (2010), 767–772, 10.1016/j.bbrc.2010.02.078.
235. [235] Faklaris, O., Cottet, M., Falco, A., Villier, B., Laget, M., Zwier, J.M., Trinquet, E., Mouillac, B., Pin, J.P., Durroux, T., Multicolor time-resolved forster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes. FASEB J. 29:6 (2015), 2235–2246, 10.1096/fj.14-260059.
236. [236] Stanasila, L., Perez, J.B., Vogel, H., Cotecchia, S., Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J. Biol. Chem. 278:41 (2003), 40239–40251, 10.1074/jbc.M306085200.
237. [237] Tautermann, C.S., GPCR structures in drug design, emerging opportunities with new structures. Bioorg. Med. Chem. Lett. 24:17 (2014), 4073–4079, 10.1016/j.bmcl.2014.07.009.
238. [238] Franco, R., Casado, V., Cortes, A., Mallol, J., Ciruela, F., Ferre, S., Lluis, C., Canela, E.I., G-protein-coupled receptor heteromers: function and ligand pharmacology. Br. J. Pharmacol. 153:Suppl. (1) (2008), S90–S98, 10.1038/sj.bjp.0707571.
239. [239] Albizu, L., Moreno, J.L., Gonzalez-Maeso, J., Sealfon, S.C., Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol. Disord. Drug Targets 9:5 (2010), 636–650.
240. [240] Ferre, S., Navarro, G., Casado, V., Cortes, A., Mallol, J., Canela, E.I., Lluis, C., Franco, R., G protein-coupled receptor heteromers as new targets for drug development. Prog. Mol. Biol. Transl. Sci. 91 (2010), 41–52, 10.1016/s1877-1173(10)91002-8.
241. [241] Schiffmann, S.N., Vanderhaeghen, J.J., Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. Off. J. Soc. Neurosci. 13:3 (1993), 1080–1087.
242. [242] Ferre, S., Quiroz, C., Woods, A.S., Cunha, R., Popoli, P., Ciruela, F., Lluis, C., Franco, R., Azdad, K., Schiffmann, S.N., An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des. 14:15 (2008), 1468–1474.
243. [243] Simola, N., Fenu, S., Baraldi, P.G., Tabrizi, M.A., Morelli, M., Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists. Exp. Neurol. 202:1 (2006), 255–257, 10.1016/j.expneurol.2006.05.015.
244. [244] Akhondzadeh, S., Shasavand, E., Jamilian, H., Shabestari, O., Kamalipour, A., Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther. 25:2 (2000), 131–137.
245. [245] Hasbi, A., Perreault, M.L., Shen, M.Y., Zhang, L., To, R., Fan, T., Nguyen, T., Ji, X., O'Dowd, B.F., George, S.R., A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism. FASEB J. 28:11 (2014), 4806–4820, 10.1096/fj.14-254037.
246. [246] Toda, S., Alguacil, L.F., Kalivas, P.W., Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J. Neurochem. 87:6 (2003), 1478–1484.
247. [247] Moreno, E., Moreno-Delgado, D., Navarro, G., Hoffmann, H.M., Fuentes, S., Rosell-Vilar, S., Gasperini, P., Rodriguez-Ruiz, M., Medrano, M., Mallol, J., Cortes, A., Casado, V., Lluis, C., Ferre, S., Ortiz, J., Canela, E., McCormick, P.J., Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: sigma1-D1-H3 receptor complexes as key targets for reducing cocaine's effects. J. Neurosc. Off. J. Soc. Neurosci. 34:10 (2014), 3545–3558, 10.1523/jneurosci.4147-13.
248. [248] Maldonado, R., Berrendero, F., Ozaita, A., Robledo, P., Neurochemical basis of cannabis addiction. Neuroscience 181 (2011), 1–17, 10.1016/j.neuroscience.2011.02.035.
249. [249] Rose, A.S., Elgeti, M., Zachariae, U., Grubmuller, H., Hofmann, K.P., Scheerer, P., Hildebrand, P.W., Position of transmembrane helix 6 determines receptor G protein coupling specificity. J. Am. Chem. Soc., 2014, 10.1021/ja5055109.
250. [250] Baba, K., Benleulmi-Chaachoua, A., Journe, A.S., Kamal, M., Guillaume, J.L., Dussaud, S., Gbahou, F., Yettou, K., Liu, C., Contreras-Alcantara, S., Jockers, R., Tosini, G., Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci. Signal., 6(296), 2013, ra89, 10.1126/scisignal.2004302.
251. [251] Kabli, N., Martin, N., Fan, T., Nguyen, T., Hasbi, A., Balboni, G., O'Dowd, B.F., George, S.R., Agonists at the delta-opioid receptor modify the binding of micro-receptor agonists to the micro-delta receptor hetero-oligomer. Br. J. Pharmacol. 161:5 (2010), 1122–1136.
252. [252] Gomes, I., Gupta, A., Filipovska, J., Szeto, H.H., Pintar, J.E., Devi, L.A., A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. U. S. A. 101:14 (2004), 5135–5139.
253. [253] Bushlin, I., Gupta, A., Stockton, S.D. Jr., Miller, L.K., Devi, L.A., Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One, 7(12), 2012, e49789.
254. [254] Biebermann, H., Krude, H., Elsner, A., Chubanov, V., Gudermann, T., Gruters, A., Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52:12 (2003), 2984–2988.
255. [255] Kopanchuk, S., Veiksina, S., Mutulis, F., Mutule, I., Yahorava, S., Mandrika, I., Petrovska, R., Rinken, A., Wikberg, J.E., Kinetic evidence for tandemly arranged ligand binding sites in melanocortin 4 receptor complexes. Neurochem. Int. 49:5 (2006), 533–542, 10.1016/j.neuint.2006.04.006.
256. [256] Rediger, A., Tarnow, P., Bickenbach, A., Schaefer, M., Krude, H., Gruters, A., Biebermann, H., Heterodimerization of hypothalamic G-protein-coupled receptors involved in weight regulation. Obes Facts 2:2 (2009), 80–86, 10.1159/000209862.
257. [257] Piechowski, C.L., Rediger, A., Lagemann, C., Muhlhaus, J., Muller, A., Pratzka, J., Tarnow, P., Gruters, A., Krude, H., Kleinau, G., Biebermann, H., Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. J. Mol. Endocrinol. 51:1 (2013), 109–118, 10.1530/jme-13-0061.
258. [258] McGraw, D.W., Mihlbachler, K.A., Schwarb, M.R., Rahman, F.F., Small, K.M., Almoosa, K.F., Liggett, S.B., Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J. Clin. Invest. 116:5 (2006), 1400–1409, 10.1172/jci25840.
259. [259] Rozenfeld, R., Devi, L.A., Receptor heteromerization and drug discovery. Trends Pharmacol. Sci. 31:3 (2010), 124–130, 10.1016/j.tips.2009.11.008.
260. [260] Zhang, Z.J., Jiang, X.L., Zhang, S.E., Hough, C.J., Li, H., Chen, J.G., Zhen, X.C., The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm. Neurosci. Lett. 382:1-2 (2005), 134–138, 10.1016/j.neulet.2005.03.001.
261. [261] Waldhoer, M., Fong, J., Jones, R.M., Lunzer, M.M., Sharma, S.K., Kostenis, E., Portoghese, P.S., Whistler, J.L., A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U. S. A. 102:25 (2005), 9050–9055, 10.1073/pnas.0501112102.
262. [262] Glass, M., Govindpani, K., Furkert, D.P., Hurst, D.P., Reggio, P.H., Flanagan, J.U., One for the price of two are bivalent ligands targeting cannabinoid receptor dimers capable of simultaneously binding to both receptors?. Trends Pharmacol. Sci. 37:5 (2016), 353–363, 10.1016/j.tips.2016.01.010.
263. [263] Vendrell, M., Angulo, E., Casado, V., Lluis, C., Franco, R., Albericio, F., Royo, M., Novel ergopeptides as dual ligands for adenosine and dopamine receptors. J. Med. Chem. 50:13 (2007), 3062–3069, 10.1021/jm060947x.
264. [264] Daniels, D.J., Lenard, N.R., Etienne, C.L., Law, P.Y., Roerig, S.C., Portoghese, P.S., Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. U. S. A. 102:52 (2005), 19208–19213, 10.1073/pnas.0506627102.
265. [265] Jorg, M., May, L.T., Mak, F.S., Lee, K.C., Miller, N.D., Scammells, P.J., Capuano, B., Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease. J. Med. Chem. 58:2 (2015), 718–738, 10.1021/jm501254d.